NCT06954740View on ClinicalTrials.gov

Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

May 15, 2026

Study Completion Date

May 15, 2028

Conditions
Acute Kidney Injury
Interventions
DRUG

Amimestrocel

Amimestrocel will be administered at a target dose of 1×10E6 MSCs/kg body weight on day 1, 4, 8, 15.

Trial Locations (6)

100010

RECRUITING

Beijing hospital, Beijing

100029

RECRUITING

China-Japan Friendship Hospital, Beijing

100050

RECRUITING

Capital Medical University Affiliated Beijing Friendship Hospital, Beijing

100053

RECRUITING

Xuanwu Hospital, Capital Medical University, Beijing

100853

RECRUITING

Chinese PLA General Hospital, Beijing

Unknown

NOT_YET_RECRUITING

Beijing Tsinghua Changgung Hospital, Medical Center, Tsinghua University, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT06954740 - Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury | Biotech Hunter | Biotech Hunter